<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01791049</url>
  </required_header>
  <id_info>
    <org_study_id>0098</org_study_id>
    <nct_id>NCT01791049</nct_id>
  </id_info>
  <brief_title>TD-1607 SAD Study in Healthy Subjects</brief_title>
  <official_title>A Randomized, Double-Blind, Placebo-Controlled, Single Ascending Dose (SAD) Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of TD-1607, a Glycopeptide-Cephalosporin Heterodimer Gram-Positive Antibiotic, in Healthy Subjects</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Theravance Biopharma</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Theravance Biopharma</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      TD-1607, administered intravenously as single doses, will be investigated in healthy subjects&#xD;
      to assess its tolerability, safety, and pharmacokinetics.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>April 2013</start_date>
  <completion_date type="Actual">October 2013</completion_date>
  <primary_completion_date type="Actual">August 2013</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Triple (Participant, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Safety and tolerability</measure>
    <time_frame>11 days</time_frame>
    <description>Adverse events, laboratory abnormalities, ECGs, and vital sign measurements.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Pharmacokinetics</measure>
    <time_frame>96 hours</time_frame>
    <description>Cmax, Tmax, AUC0-t, AUC0-24, AUCinf, CL, Vdss, t1/2, amount excreted in urine (Ae), fraction eliminated in urine (fe), and CLr.</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">64</enrollment>
  <condition>Serious Infections Due to Known or Suspected Gram-positive Pathogens</condition>
  <arm_group>
    <arm_group_label>Active</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Single escalating doses of TD-1607, administered intravenously</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Placebo</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>TD-1607</intervention_name>
    <arm_group_label>Active</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Subject is a healthy nonsmoking male or a female of non-child bearing potential and 18&#xD;
             to 50 years old, inclusive, at Screening. Females are considered to be of&#xD;
             non-childbearing potential if they have had a hysterectomy or tubal ligation or are&#xD;
             postmenopausal (amenorrheic for at least 2 years) with a follicle-stimulating hormone&#xD;
             (FSH) level &gt;20 IU/L.&#xD;
&#xD;
          -  Subject has a body mass index (BMI) of 19 to 30 kg/m2, inclusive, and weighs at least&#xD;
             50 kg&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Subject has evidence or history of clinically significant allergic (except for&#xD;
             untreated, asymptomatic seasonal allergies at time of dosing), hematological,&#xD;
             endocrine, pulmonary, gastrointestinal, cardiovascular, hepatic, psychiatric, or&#xD;
             neurological disease.&#xD;
&#xD;
          -  Subject has a history of allergies or hypersensitivities to glycopeptide (e.g.,&#xD;
             vancomycin), penicillin, or cephalosporin antibiotics.&#xD;
&#xD;
          -  Subject has participated in another clinical trial of an investigational drug (or&#xD;
             medical device) within 60 days (or 5 half-lives, whichever is longer) prior to&#xD;
             Screening or is currently participating in another trial of an investigational drug&#xD;
             (or medical device).&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>50 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Medical Monitor</last_name>
    <role>Study Director</role>
    <affiliation>Theravance Biopharma</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>PPD Phase 1</name>
      <address>
        <city>Austin</city>
        <state>Texas</state>
        <zip>78744</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>January 2021</verification_date>
  <study_first_submitted>February 11, 2013</study_first_submitted>
  <study_first_submitted_qc>February 11, 2013</study_first_submitted_qc>
  <study_first_posted type="Estimate">February 13, 2013</study_first_posted>
  <last_update_submitted>January 15, 2021</last_update_submitted>
  <last_update_submitted_qc>January 15, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">January 19, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Gram-positive</keyword>
  <keyword>Infections</keyword>
  <keyword>Bacterial infections</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Infections</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

